With a patient-centered approach, they create personalized weight loss treatment plans tailored to individual patients
Still unlicensed in humans outside of research investor.lilly.com/news-releases/ TRIUMPH-1: #retatrutide topline data Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand): 12 mg: -28.3% body weight (-31.9 kg) 9 mg: -25.9% | 4 mg: -19.0% | Placebo: -2.2% 30% weight loss: 45.3% vs 0.5% 104-wk extension (BMI 35, n=532), 12 mg MTD: -30.3% Cross-trial context (obesity, no diabetes): STEP-1 SEMA 2.4 mg, 68 wk: -14.9% SURMOUNT-1 TZP 15 mg, 72 wk: -20.9% TRIUMPH-1 RETA 12 mg, 80 wk: -28.3% But: Topline press release
This dual-action approach enhances insulin response, curbs appetite, and slows digestion to keep you feeling fuller longer
It is not safe for one pen to be used for more than one person
Our partner pharmacy will then expedite shipping of your GLP-1 vial prescription (and supplies, if applicable) direct to your doorstep
1999 Aug;18(4):289-95.Carnitine increases glucose disposal in humans